Cyclacel to Participate in 31st Annual ROTH Conference March 18-19
March 13 2019 - 7:00AM
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP)
(Cyclacel or the Company), a biopharmaceutical company developing
innovative medicines based on cancer cell biology, announced that
it will participate in the 31st Annual ROTH Capital Partners
Conference, which will be held March 18-19, 2019 at the
Ritz-Carlton in Dana Point, California.
A webcast presentation of recent developments at the company may
be accessed through the conference website at
http://wsw.com/webcast/roth33/cycc/.
In addition, management will hold one-on-one meetings with
investors during the conference. For additional conference
information or to schedule a one-on-one meeting with Cyclacel
please email oneononerequests@roth.com or contact your ROTH
representative.
About Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical
company using its expertise in cell cycle, transcriptional
regulation and DNA damage response biology in cancer cells to
develop innovative medicines. The transcriptional regulation
program is evaluating CYC065, a CDK inhibitor, in patients with
advanced solid cancers and in combination with venetoclax in
patients with advanced hematological malignancies, including CLL
and AML. The DNA damage response program is evaluating a sequential
regimen of sapacitabine and seliciclib, a CDK inhibitor, in BRCA
positive patients with advanced solid cancers and a concomitant
regimen of sapacitabine and olaparib, a PARP inhibitor, in BRCA
positive patients with breast cancer. CYC140, a PLK inhibitor, is
in a Phase 1 first-in-human study in patients with advanced
leukemias. Cyclacel's strategy is to build a diversified
biopharmaceutical business focused in hematology and oncology based
on a pipeline of novel drug candidates. For additional information,
please visit www.cyclacel.com.
Forward-looking Statements
This news release contains certain forward-looking statements
that involve risks and uncertainties that could cause actual
results to be materially different from historical results or from
any future results expressed or implied by such forward-looking
statements. Such forward-looking statements include statements
regarding, among other things, the efficacy, safety and intended
utilization of Cyclacel's product candidates, the conduct and
results of future clinical trials, plans regarding regulatory
filings, future research and clinical trials and plans regarding
partnering activities. Factors that may cause actual results to
differ materially include the risk that product candidates that
appeared promising in early research and clinical trials do not
demonstrate safety and/or efficacy in larger-scale or later
clinical trials, trials may have difficulty enrolling, Cyclacel may
not obtain approval to market its product candidates, the risks
associated with reliance on outside financing to meet capital
requirements, and the risks associated with reliance on
collaborative partners for further clinical trials, development and
commercialization of product candidates. You are urged to consider
statements that include the words "may," "will," "would," "could,"
"should," "believes," "estimates," "projects," "potential,"
"expects," "plans," "anticipates," "intends," "continues,"
"forecast," "designed," "goal," or the negative of those words or
other comparable words to be uncertain and forward-looking. For a
further list and description of the risks and uncertainties the
Company faces, please refer to our most recent Annual Report on
Form 10-K and other periodic and other filings we file with the
Securities and Exchange Commission and are available at
www.sec.gov. Such forward-looking statements are current only as of
the date they are made, and we assume no obligation to update any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contacts |
|
Company: |
Paul McBarron, (908)
517-7330, pmcbarron@cyclacel.com |
Investor
Relations: |
Russo Partners LLC,
Alexander Fudukidis, (646) 942-5632,
alex.fudukidis@russopartnersllc.com |
© Copyright 2019 Cyclacel Pharmaceuticals, Inc. All Rights
Reserved. The Cyclacel logo and Cyclacel® are trademarks of
Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Historical Stock Chart
From Sep 2023 to Sep 2024